ReviewGenome medicine2016
Technological considerations for genome-guided diagnosis and management of cancer.
Review in Genome medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Whole exome sequencing identifies somatically mutated genes in bladder cancer: A pilot study from Bangladesh.Biochemistry and biophysics reports · 2026Article
- Emerging role of low-frequency somatic mutations in cancer relapse: from early detection to precision oncology.Frontiers in oncology · 2026Review
- Clinical utility of 'Shaken' biopsies for whole-genome sequencing.Journal of clinical pathology · 2025Article
- Internal Standards for Limit Controls and Absolute Abundance Measurement of Oncogenic Fusions and Mutations.The journal of applied laboratory medicine · 2024Article
- Nuclease Enrichment and qPCR Detection of Rare Nucleotide Variants.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Article
- Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing.International journal of molecular sciences · 2022Article
- Regulatory pattern of abnormal promoter CpG island methylation in the glioblastoma multiforme classification.Frontiers in genetics · 2022Article
- The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer.Translational lung cancer research · 2020Review
- PIK3CA mutation enrichment and quantitation from blood and tissue.Scientific reports · 2020Article
- Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis.Critical reviews in clinical laboratory sciences · 2018Review
- Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes.Journal of molecular medicine (Berlin, Germany) · 2017Review
- Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies.Clinical chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Technological, methodological, and analytical advances continue to improve the resolution of our view into the cancer genome, even as we discover ways to carry out analyses at greater distances from the primary tumor sites. These advances are finally making the integration of cancer genomic profiling into clinical practice feasible. Formalin fixation and paraffin embedding, which has long been the default pathological biopsy medium, is now being supplemented with liquid biopsy as a means to profile the cancer genomes of patients. At each stage of the genomic data generation process-sample collection, preservation, storage, extraction, library construction, sequencing, and variant calling-there are variables that impact the sensitivity and specificity of the analytical result and the clinical utility of the test. These variables include sample degradation, low yields of nucleic acid, and low variant allele fractions (proportions of assayed molecules carrying variant allele(s)). We review here the most common pre-analytical and analytical factors relating to routine cancer patient genome profiling, some solutions to common challenges, and the major sample preparation and sequencing technology choices available today.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.